Research ExplorerPublicationsDynamic of bone marrow fibrosis regression predicts survival...

Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis

Standard

Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis. / Kröger, Nicolaus; Zabelina, Tatiana; Alchalby, Haefaa; Stübig, Thomas; Wolschke, Christine; Ayuketang, Francis Ayuk; von Huenerbein, Natascha; Kvasnicka, Hans-Michael; Thiele, Jürgen; Kreipe, Hans-Heinrich; Büsche, Guntram.

In: BIOL BLOOD MARROW TR, Vol. 20, No. 6, 01.06.2014, p. 812-5.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kröger, N, Zabelina, T, Alchalby, H, Stübig, T, Wolschke, C, Ayuketang, FA, von Huenerbein, N, Kvasnicka, H-M, Thiele, J, Kreipe, H-H & Büsche, G 2014, 'Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis', BIOL BLOOD MARROW TR, vol. 20, no. 6, pp. 812-5. https://doi.org/10.1016/j.bbmt.2014.02.019

APA

Kröger, N., Zabelina, T., Alchalby, H., Stübig, T., Wolschke, C., Ayuketang, F. A., von Huenerbein, N., Kvasnicka, H-M., Thiele, J., Kreipe, H-H., & Büsche, G. (2014). Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis. BIOL BLOOD MARROW TR, 20(6), 812-5. https://doi.org/10.1016/j.bbmt.2014.02.019

Vancouver

Kröger N, Zabelina T, Alchalby H, Stübig T, Wolschke C, Ayuketang FA et al. Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis. BIOL BLOOD MARROW TR. 2014 Jun 1;20(6):812-5. https://doi.org/10.1016/j.bbmt.2014.02.019

Bibtex

@article{81f8622bbbde4b6ab0e11f3b0a4ab8a2,
title = "Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis",
abstract = "We correlate regression of bone marrow fibrosis (BMF) on day 30 and 100 after dose- reduced allogeneic stem cell transplantation (allo-SCT) in 57 patients with primary or post-essential thrombocythemia/polycythemia vera myelofibrosis with graft function and survival. The distribution of International Prognostic Scoring System (IPSS) risk score categories was 1 patient with low risk, 5 patients with intermediate-1 risk, 18 patients with intermediate-2 risk, and 33 patients with high risk. Before allo-SCT, 41 patients (72%) were classified as XXX [myclofibrosis (MF)]-3 and 16 (28%) were classified as MF-2 according to the World Health Organization criteria. At postengraftment day +30 (±10 days), 21% of the patients had near-complete or complete regression of BMF (MF-0/-1), and on day +100 (±20 days), 54% were MF-0/-1. The 5-year overall survival rate at day +100 was 96% in patients with MF-0/-1 and 57% for those with MF-2/-3 (P = .04). There was no difference in BMF regression at day +100 between IPSS high-risk and low/intermediate-risk patients. Complete donor cell chimerism at day +100 was seen in 81% of patients with MF-0/-1 and in 31% of those with MF-2/-3. Patients with MF-2/-3 at day +100 were more likely to be transfusion-dependent for either RBCs (P = .014) or platelets (P = .018). Rapid BMF regression after reduced-intensity conditioning allo-SCT resulted in a favorable survival independent of IPSS risk score at transplantation.",
author = "Nicolaus Kr{\"o}ger and Tatiana Zabelina and Haefaa Alchalby and Thomas St{\"u}big and Christine Wolschke and Ayuketang, {Francis Ayuk} and {von Huenerbein}, Natascha and Hans-Michael Kvasnicka and J{\"u}rgen Thiele and Hans-Heinrich Kreipe and Guntram B{\"u}sche",
note = "Copyright {\textcopyright} 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.",
year = "2014",
month = jun,
day = "1",
doi = "10.1016/j.bbmt.2014.02.019",
language = "English",
volume = "20",
pages = "812--5",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "6",

}

RIS

TY - JOUR

T1 - Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis

AU - Kröger, Nicolaus

AU - Zabelina, Tatiana

AU - Alchalby, Haefaa

AU - Stübig, Thomas

AU - Wolschke, Christine

AU - Ayuketang, Francis Ayuk

AU - von Huenerbein, Natascha

AU - Kvasnicka, Hans-Michael

AU - Thiele, Jürgen

AU - Kreipe, Hans-Heinrich

AU - Büsche, Guntram

N1 - Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

PY - 2014/6/1

Y1 - 2014/6/1

N2 - We correlate regression of bone marrow fibrosis (BMF) on day 30 and 100 after dose- reduced allogeneic stem cell transplantation (allo-SCT) in 57 patients with primary or post-essential thrombocythemia/polycythemia vera myelofibrosis with graft function and survival. The distribution of International Prognostic Scoring System (IPSS) risk score categories was 1 patient with low risk, 5 patients with intermediate-1 risk, 18 patients with intermediate-2 risk, and 33 patients with high risk. Before allo-SCT, 41 patients (72%) were classified as XXX [myclofibrosis (MF)]-3 and 16 (28%) were classified as MF-2 according to the World Health Organization criteria. At postengraftment day +30 (±10 days), 21% of the patients had near-complete or complete regression of BMF (MF-0/-1), and on day +100 (±20 days), 54% were MF-0/-1. The 5-year overall survival rate at day +100 was 96% in patients with MF-0/-1 and 57% for those with MF-2/-3 (P = .04). There was no difference in BMF regression at day +100 between IPSS high-risk and low/intermediate-risk patients. Complete donor cell chimerism at day +100 was seen in 81% of patients with MF-0/-1 and in 31% of those with MF-2/-3. Patients with MF-2/-3 at day +100 were more likely to be transfusion-dependent for either RBCs (P = .014) or platelets (P = .018). Rapid BMF regression after reduced-intensity conditioning allo-SCT resulted in a favorable survival independent of IPSS risk score at transplantation.

AB - We correlate regression of bone marrow fibrosis (BMF) on day 30 and 100 after dose- reduced allogeneic stem cell transplantation (allo-SCT) in 57 patients with primary or post-essential thrombocythemia/polycythemia vera myelofibrosis with graft function and survival. The distribution of International Prognostic Scoring System (IPSS) risk score categories was 1 patient with low risk, 5 patients with intermediate-1 risk, 18 patients with intermediate-2 risk, and 33 patients with high risk. Before allo-SCT, 41 patients (72%) were classified as XXX [myclofibrosis (MF)]-3 and 16 (28%) were classified as MF-2 according to the World Health Organization criteria. At postengraftment day +30 (±10 days), 21% of the patients had near-complete or complete regression of BMF (MF-0/-1), and on day +100 (±20 days), 54% were MF-0/-1. The 5-year overall survival rate at day +100 was 96% in patients with MF-0/-1 and 57% for those with MF-2/-3 (P = .04). There was no difference in BMF regression at day +100 between IPSS high-risk and low/intermediate-risk patients. Complete donor cell chimerism at day +100 was seen in 81% of patients with MF-0/-1 and in 31% of those with MF-2/-3. Patients with MF-2/-3 at day +100 were more likely to be transfusion-dependent for either RBCs (P = .014) or platelets (P = .018). Rapid BMF regression after reduced-intensity conditioning allo-SCT resulted in a favorable survival independent of IPSS risk score at transplantation.

U2 - 10.1016/j.bbmt.2014.02.019

DO - 10.1016/j.bbmt.2014.02.019

M3 - SCORING: Journal article

C2 - 24589549

VL - 20

SP - 812

EP - 815

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 6

ER -